parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.05 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including microglia; strongest in choroid plexus epithelial cells	0.75
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	4 Parkinson's papers of 62	0.79
pathways Reactome	2 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 5261

SLC33A1 in dopamine neurons, braak+0.00 (p 1.000) → +0.00 (p 1.000)receipt 5271
SLC33A1 in microglia, braak+0.34 (p 0.374) → +0.03 (p 0.946)receipt 5270

receipt 5271: SLC33A1 in dopamine neurons, braak

power: full sample +0.11 (p 0.671, n 18), 95% CI -0.38 to +0.55. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.16 (p 0.515, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.24 (p 0.328, n 18). could be the mix.
skeptic: leave-one-out range +0.00 to +0.25, sign flips 0; without severely affected donors +0.11 (p 0.671, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for SLC33A1 in dopamine neurons.

case closed: nothing better to follow up.

receipt 5270: SLC33A1 in microglia, braak

power: full sample +0.11 (p 0.664, n 18), 95% CI -0.38 to +0.55. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.15 (p 0.549, n 18). does not hold up.
composition: microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: +0.12 (p 0.640, n 18). could be the mix.
skeptic: leave-one-out range -0.03 to +0.20, sign flips 2; without severely affected donors +0.11 (p 0.664, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for SLC33A1 in microglia.

case closed: nothing better to follow up.

loading the receipts